IMVT
Immunovant, Inc.$39.69+0.92 (+2.37%)Prev Close$38.77·MCap$8.15B·P/E—·Vol433.7K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
34
$15.04M
◆
Net Activity
Net Seller
$15.04M
●
Active Insiders
10
last 12 mo
Over the past 12 months, insider activity at Immunovant, Inc. (IMVT) has been exclusively selling, with 0 insider purchases totaling $0.00 and 34 insider sales totaling $15.04M. The most recent insider transaction was by Van Tuyl Christopher (officer: Chief Legal Officer), who sold $47.7K worth of shares on Jul 10, 2026. Immunovant, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $8.15B.
IMVT Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jul 10, 2026 | Van Tuyl Christopher | officer: Chief Legal Officer | Sell | 1,206 | $39.55 | $47.7K | 179,454 |
| Jul 10, 2026 | Gloria Melanie | officer: Chief Operating Officer | Sell | 2,036 | $39.55 | $80.5K | 222,463 |
| Jul 10, 2026 | Stout Jay S | officer: Chief Technology Officer | Sell | 3,487 | $39.55 | $137.9K | 209,779 |
| Jul 6, 2026 | Venker Eric | director, officer: Chief Executive Officer | Sell | 3,092 | $38.48 | $119.0K | 254,280 |
| Jun 26, 2026 | Girao Tiago | officer: Chief Financial Officer | Sell | 10,000 | $38.46 | $384.6K | 247,596 |
| Jun 26, 2026 | Gloria Melanie | officer: Chief Operating Officer | Sell | 17,714 | $38.31 | $678.6K | 227,359 |
| Jun 26, 2026 | Pande Atul | director | Sell | 1,500 | $38.01 | $57.0K | 116,731 |
| Jun 26, 2026 | Stout Jay S | officer: Chief Technology Officer | Sell | 40,000 | $38.31 | $1.53M | 218,408 |
| Jun 26, 2026 | Van Tuyl Christopher | officer: Chief Legal Officer | Sell | 17,824 | $38.31 | $682.9K | 183,439 |
| Jun 22, 2026 | Van Tuyl Christopher | officer: Chief Legal Officer | Sell | 2,634 | $35.39 | $93.2K | 180,597 |
| Jun 16, 2026 | Pande Atul | director | Sell | 1,500 | $34.02 | $51.0K | 116,731 |
| May 29, 2026 | Fromkin Andrew J. | director | Sell | 221,951 | $33.51 | $7.44M | 284,850-44% |
| May 22, 2026 | Gloria Melanie | officer: Chief Operating Officer | Sell | 3,115 | $32.45 | $101.1K | 244,973 |
| May 20, 2026 | Pande Atul | director | Sell | 6,000 | $32.00 | $192.0K | 116,731 |
| May 1, 2026 | Susman Robert Graham | director | Sell | 2,502 | $27.17 | $68.0K | 36,394 |
| Apr 24, 2026 | Stout Jay S | officer: Chief Technology Officer | Sell | 2,754 | $29.62 | $81.6K | 251,685 |
| Apr 24, 2026 | Girao Tiago | officer: Chief Financial Officer | Sell | 25,760 | $29.62 | $763.0K | 247,596 |
| Apr 10, 2026 | Stout Jay S | officer: Chief Technology Officer | Sell | 10,132 | $24.83 | $251.6K | 255,957 |
| Apr 10, 2026 | Van Tuyl Christopher | officer: Chief Legal Officer | Sell | 5,165 | $24.83 | $128.2K | 183,231 |
| Apr 10, 2026 | Gloria Melanie | officer: Chief Operating Officer | Sell | 8,722 | $24.83 | $216.6K | 245,222 |
| Mar 20, 2026 | Van Tuyl Christopher | officer: Chief Legal Officer | Sell | 2,877 | $24.97 | $71.8K | 147,053 |
| Feb 27, 2026 | Gloria Melanie | officer: Chief Operating Officer | Sell | 3,238 | $27.85 | $90.2K | 172,074 |
| Jan 21, 2026 | Stout Jay S | Chief Technology Officer | Sell | 1,977 | $26.03 | $51.5K | 0 |
| Jan 7, 2026 | Stout Jay S | Chief Technology Officer | Sell | 1,203 | $26.53 | $31.9K | 0 |
| Dec 18, 2025 | Van Tuyl Christopher | Chief Legal Officer | Sell | 10,813 | $26.91 | $290.9K | 0 |
| Dec 1, 2025 | Fromkin Andrew J. | Director | Sell | 22,249 | $23.25 | $517.2K | 0 |
| Dec 1, 2025 | Hughes Douglas J. | Director | Sell | 15,000 | $23.24 | $348.7K | 0 |
| Nov 20, 2025 | Gloria Melanie | Chief Operating Officer | Sell | 12,626 | $23.62 | $298.2K | 0 |
| Oct 22, 2025 | Geffner Michael | Chief Medical Officer | Sell | 2,595 | $19.03 | $49.4K | 0 |
| Oct 22, 2025 | Stout Jay S | Chief Technology Officer | Sell | 2,520 | $19.03 | $48.0K | 0 |
| Oct 8, 2025 | Geffner Michael | Chief Medical Officer | Sell | 1,272 | $16.30 | $20.7K | 0 |
| Oct 8, 2025 | Stout Jay S | Chief Technology Officer | Sell | 1,585 | $16.30 | $25.8K | 0 |
| Jul 23, 2025 | Geffner Michael | Chief Medical Officer | Sell | 2,385 | $18.15 | $43.3K | 0 |
| Jul 23, 2025 | Stout Jay S | Chief Technology Officer | Sell | 2,805 | $18.15 | $50.9K | 0 |
| Jul 9, 2025 | Geffner Michael | Chief Medical Officer | Sell | 1,160 | $17.24 | $20.0K | 0 |
| Jul 9, 2025 | Stout Jay S | Chief Technology Officer | Sell | 1,519 | $17.24 | $26.2K | 0 |
| Apr 23, 2025 | Geffner Michael | Chief Medical Officer | Sell | 2,349 | $14.79 | $34.7K | 0 |
| Apr 23, 2025 | Stout Jay S | Chief Technology Officer | Sell | 1,925 | $14.79 | $28.5K | 0 |
| Apr 16, 2025 | Barnett Eva Renee | Chief Financial Officer | Sell | 2,993 | $14.89 | $44.6K | 0 |
| Apr 16, 2025 | Salzmann Peter | Chief Executive Officer | Sell | 8,321 | $14.89 | $123.9K | 0 |
| Apr 9, 2025 | Barnett Eva Renee | Chief Financial Officer | Sell | 11,063 | $12.99 | $143.7K | 0 |
| Apr 9, 2025 | Geffner Michael | Chief Medical Officer | Sell | 6,169 | $12.99 | $80.1K | 0 |
| Apr 9, 2025 | Salzmann Peter | Chief Executive Officer | Sell | 28,094 | $12.99 | $364.9K | 0 |
| Apr 9, 2025 | Stout Jay S | Chief Technology Officer | Sell | 5,004 | $12.99 | $65.0K | 0 |
| Mar 7, 2025 | Fromkin Andrew J. | Director | Sell | 8,000 | $19.60 | $156.8K | 0 |
| Feb 21, 2025 | Barnett Eva Renee | Chief Financial Officer | Sell | 2,814 | $20.86 | $58.7K | 321,952 |
| Feb 21, 2025 | Macias William L. | Chief Medical Officer | Sell | 2,055 | $20.86 | $42.9K | 357,353 |
| Feb 21, 2025 | Salzmann Peter | Chief Executive Officer | Sell | 15,439 | $20.86 | $322.1K | 948,786 |
| Jan 24, 2025 | Geffner Michael | Chief Medical Officer | Sell | 2,657 | $23.59 | $62.7K | 132,314 |
| Jan 24, 2025 | Stout Jay S | Chief Technology Officer | Sell | 2,195 | $23.59 | $51.8K | 139,991 |
Showing 1–50 of 182
1 / 4
IMVT Insider Buying Activity
The following table shows recent insider purchases of Immunovant, Inc. (IMVT) stock reported via SEC Form 4 filings.
No insider buying activity found for IMVT in the last 12 months.
IMVT Insider Selling Activity
The following table shows recent insider sales of Immunovant, Inc. (IMVT) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jul 10, 2026 | Van Tuyl Christopher | officer: Chief Legal Officer | Sell | 1,206 | $39.55 | $47.7K | 179,454 |
| Jul 10, 2026 | Gloria Melanie | officer: Chief Operating Officer | Sell | 2,036 | $39.55 | $80.5K | 222,463 |
| Jul 10, 2026 | Stout Jay S | officer: Chief Technology Officer | Sell | 3,487 | $39.55 | $137.9K | 209,779 |
| Jul 6, 2026 | Venker Eric | director, officer: Chief Executive Officer | Sell | 3,092 | $38.48 | $119.0K | 254,280 |
| Jun 26, 2026 | Girao Tiago | officer: Chief Financial Officer | Sell | 10,000 | $38.46 | $384.6K | 247,596 |
| Jun 26, 2026 | Gloria Melanie | officer: Chief Operating Officer | Sell | 17,714 | $38.31 | $678.6K | 227,359 |
| Jun 26, 2026 | Pande Atul | director | Sell | 1,500 | $38.01 | $57.0K | 116,731 |
| Jun 26, 2026 | Stout Jay S | officer: Chief Technology Officer | Sell | 40,000 | $38.31 | $1.53M | 218,408 |
| Jun 26, 2026 | Van Tuyl Christopher | officer: Chief Legal Officer | Sell | 17,824 | $38.31 | $682.9K | 183,439 |
| Jun 22, 2026 | Van Tuyl Christopher | officer: Chief Legal Officer | Sell | 2,634 | $35.39 | $93.2K | 180,597 |
| Jun 16, 2026 | Pande Atul | director | Sell | 1,500 | $34.02 | $51.0K | 116,731 |
| May 29, 2026 | Fromkin Andrew J. | director | Sell | 221,951 | $33.51 | $7.44M | 284,850-44% |
| May 22, 2026 | Gloria Melanie | officer: Chief Operating Officer | Sell | 3,115 | $32.45 | $101.1K | 244,973 |
| May 20, 2026 | Pande Atul | director | Sell | 6,000 | $32.00 | $192.0K | 116,731 |
| May 1, 2026 | Susman Robert Graham | director | Sell | 2,502 | $27.17 | $68.0K | 36,394 |
| Apr 24, 2026 | Stout Jay S | officer: Chief Technology Officer | Sell | 2,754 | $29.62 | $81.6K | 251,685 |
| Apr 24, 2026 | Girao Tiago | officer: Chief Financial Officer | Sell | 25,760 | $29.62 | $763.0K | 247,596 |
| Apr 10, 2026 | Stout Jay S | officer: Chief Technology Officer | Sell | 10,132 | $24.83 | $251.6K | 255,957 |
| Apr 10, 2026 | Van Tuyl Christopher | officer: Chief Legal Officer | Sell | 5,165 | $24.83 | $128.2K | 183,231 |
| Apr 10, 2026 | Gloria Melanie | officer: Chief Operating Officer | Sell | 8,722 | $24.83 | $216.6K | 245,222 |
| Mar 20, 2026 | Van Tuyl Christopher | officer: Chief Legal Officer | Sell | 2,877 | $24.97 | $71.8K | 147,053 |
| Feb 27, 2026 | Gloria Melanie | officer: Chief Operating Officer | Sell | 3,238 | $27.85 | $90.2K | 172,074 |
| Jan 21, 2026 | Stout Jay S | Chief Technology Officer | Sell | 1,977 | $26.03 | $51.5K | 0 |
| Jan 7, 2026 | Stout Jay S | Chief Technology Officer | Sell | 1,203 | $26.53 | $31.9K | 0 |
| Dec 18, 2025 | Van Tuyl Christopher | Chief Legal Officer | Sell | 10,813 | $26.91 | $290.9K | 0 |
| Dec 1, 2025 | Fromkin Andrew J. | Director | Sell | 22,249 | $23.25 | $517.2K | 0 |
| Dec 1, 2025 | Hughes Douglas J. | Director | Sell | 15,000 | $23.24 | $348.7K | 0 |
| Nov 20, 2025 | Gloria Melanie | Chief Operating Officer | Sell | 12,626 | $23.62 | $298.2K | 0 |
| Oct 22, 2025 | Geffner Michael | Chief Medical Officer | Sell | 2,595 | $19.03 | $49.4K | 0 |
| Oct 22, 2025 | Stout Jay S | Chief Technology Officer | Sell | 2,520 | $19.03 | $48.0K | 0 |
| Oct 8, 2025 | Geffner Michael | Chief Medical Officer | Sell | 1,272 | $16.30 | $20.7K | 0 |
| Oct 8, 2025 | Stout Jay S | Chief Technology Officer | Sell | 1,585 | $16.30 | $25.8K | 0 |
| Jul 23, 2025 | Geffner Michael | Chief Medical Officer | Sell | 2,385 | $18.15 | $43.3K | 0 |
| Jul 23, 2025 | Stout Jay S | Chief Technology Officer | Sell | 2,805 | $18.15 | $50.9K | 0 |
| Jul 9, 2025 | Geffner Michael | Chief Medical Officer | Sell | 1,160 | $17.24 | $20.0K | 0 |
| Jul 9, 2025 | Stout Jay S | Chief Technology Officer | Sell | 1,519 | $17.24 | $26.2K | 0 |
| Apr 23, 2025 | Geffner Michael | Chief Medical Officer | Sell | 2,349 | $14.79 | $34.7K | 0 |
| Apr 23, 2025 | Stout Jay S | Chief Technology Officer | Sell | 1,925 | $14.79 | $28.5K | 0 |
| Apr 16, 2025 | Barnett Eva Renee | Chief Financial Officer | Sell | 2,993 | $14.89 | $44.6K | 0 |
| Apr 16, 2025 | Salzmann Peter | Chief Executive Officer | Sell | 8,321 | $14.89 | $123.9K | 0 |
| Apr 9, 2025 | Barnett Eva Renee | Chief Financial Officer | Sell | 11,063 | $12.99 | $143.7K | 0 |
| Apr 9, 2025 | Geffner Michael | Chief Medical Officer | Sell | 6,169 | $12.99 | $80.1K | 0 |
| Apr 9, 2025 | Salzmann Peter | Chief Executive Officer | Sell | 28,094 | $12.99 | $364.9K | 0 |
| Apr 9, 2025 | Stout Jay S | Chief Technology Officer | Sell | 5,004 | $12.99 | $65.0K | 0 |
| Mar 7, 2025 | Fromkin Andrew J. | Director | Sell | 8,000 | $19.60 | $156.8K | 0 |
| Feb 21, 2025 | Barnett Eva Renee | Chief Financial Officer | Sell | 2,814 | $20.86 | $58.7K | 321,952 |
| Feb 21, 2025 | Macias William L. | Chief Medical Officer | Sell | 2,055 | $20.86 | $42.9K | 357,353 |
| Feb 21, 2025 | Salzmann Peter | Chief Executive Officer | Sell | 15,439 | $20.86 | $322.1K | 948,786 |
| Jan 24, 2025 | Geffner Michael | Chief Medical Officer | Sell | 2,657 | $23.59 | $62.7K | 132,314 |
| Jan 24, 2025 | Stout Jay S | Chief Technology Officer | Sell | 2,195 | $23.59 | $51.8K | 139,991 |
IMVT Insiders
Similar Stocks to IMVT
VRTX
Vertex Pharmaceuticals Incorporated
$476.29+0.08%
$126.50B
REGN
Regeneron Pharmaceuticals, Inc.
$662.73+1.01%
$68.29B
ALNY
Alnylam Pharmaceuticals, Inc.
$275.93-1.72%
$43.19B
RVMD
Revolution Medicines, Inc.
$185.71+0.42%
$40.34B
MRNA
Moderna, Inc.
$68.11+1.00%
$27.09B
INSM
Insmed Incorporated
$109.25-0.67%
$25.06B
INCY
Incyte Corporation
$114.43-0.30%
$23.32B
UTHR
United Therapeutics Corporation
$530.63+0.75%
$23.22B